Recent News

• 11.07.2026 - argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
• 11.03.2026 - argenx to Present at Upcoming Investor Conferences
• 10.22.2026 - argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
• 10.19.2026 - argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
• 10.15.2026 - argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
• 10.08.2026 - argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
• 10.08.2026 - argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
• 09.29.2026 - argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
• 09.17.2026 - argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
• 09.01.2026 - argenx to Present at Upcoming Investor Conferences

Recent Filings

• 11.05.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.22.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.22.2026 - EX-99.1 EX-99.1
• 10.19.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.19.2026 - EX-99.1 EX-99.1
• 10.08.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.08.2026 - EX-99.1 EX-99.1
• 09.29.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.29.2026 - EX-99.1 EX-99.1
• 08.27.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]